media – Page 28 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Plans to transfer 100% equity of Tongan Pharmaceutical to continue focusing on the biopharmaceutical track

Kexing Pharmaceuticals(688136) announced on June 11, the company plans to transfer 100% equity of its wholly-owned subsidiary Shenzhen Tongan Pharmaceutical Co., Ltd. for RMB 15 million.To Guangxi Zhuang Autonomous Region Drug Research Institute Co., Ltd. The company’s stock closed at 56.39 yuan per share on June 10, up 6.40%. Guangxi Pharmaceutical Research Institute is a high-tech enterprise dedicated to pharmaceutical research and development and innovation .Enterprise, Guangxi Specialized, Refined, Special and New Enterprise. It has 5 national exclusive varieties and nearly 40 product approvals. Its credit status is good, it has not been listed as a dishonest debtor, and it has the ability to perform its contracts. Tongan Pharmaceutical’s original main business was to produce Kehuang Capsules on behalf of the company. Now the drug has been transferred to the company’s own production. In recent years, Tongan Pharmaceutical has not actually carried out business. At present, it mainly holds 19 ...
- Source: drugdu
- 65
- June 12, 2025
LifeSense’s subsidiary’s application for renewal of Holter system registration certificate accepted

June 10, LifeSense issued an announcement that its holding subsidiary Ruikang Hongye recently received a medical deviceThe “Acceptance Certificate” for the renewal of the registration certificate has the acceptance number 0010600220250626. The product involved in this renewal application is a dynamic electrocardiogram system, which is a Class II medical device . Its registration certificate will expire on December 14, 2025, and the application renewal period is five years. In the first quarter of 2025, Lepu Medical achieved revenue of 273 million yuan and net profit attributable to shareholders of the parent company of 22.94 million yuan. https://finance.eastmoney.com/a/202506103426761085.html
- Source: drugdu
- 71
- June 12, 2025
MEDIX Japan

Organiser: Reed Exhibitions Time： October 1st – October 3rd, 2025 address：1-5-102 Minatonomori-kita, Suminoe-ku, Osaka-shi, Osaka Prefecture, Japan Exhibition hall： Intex Osaka Product range: Medical components and parts Various medical motors, electric machines, and functional components Medical pumps and valves Medical electronic components, modules, and accessories Surface treatments and coatings Tubing and extrusion processing Medical device contract manufacturing services Medical needles/tubing Various medical materials, including titanium alloys, PVC materials, etc. About MEDIX Japan： The MEDIX Japan Osaka Medical Device Exhibition is the largest-scale and highest-level exhibition for medical device components and materials in Western Japan. It brings together a comprehensive range of offerings in medical device design and development, raw materials, components, manufacturing equipment, contract customization, testing, and certification. It serves as the optimal platform for component enterprises to promote their products to medical device manufacturers.
- Source: drugdu
- 128
- June 12, 2025
Develop and issue a catalog of innovative drugs for commercial health insurance; Huahai Pharmaceutical receives FDA warning letter

Central Office and State Office: Improve the adjustment mechanism of the basic medical insurance drug catalog, formulate and introduce the innovative drug catalog for commercial health insurance On June 9th, the General Office of the Communist Party of China and the General Office of the State Council issued the “Opinions on Further Ensuring and Improving People’s Livelihood and Focusing on Solving the Urgent Difficulties and Worries of the Masses”. Promote the sharing of high-quality medical and health resources. Promote the expansion and sinking of high-quality medical resources and balanced regional layout, optimize the construction mode, management system, and operation mechanism of regional medical centers. Implement the medical and health infrastructure project, promote the sinking of urban medical resources to county-level hospitals and urban and rural grassroots, and gradually achieve full coverage of the construction of a close county-level medical community. Support high-level hospital personnel, services, technology, management, etc. to ...
- Source: drugdu
- 67
- June 11, 2025
Multiple public funds have adjusted their valuation methods for suspended stocks; Over a hundred ETFs facing liquidity crisis? 丨 Tianci Liangji Early Ginseng

NO.1 Vanguard Fund’s newly appointed Inspector General, Wang Zhongkun Recently, Vanguard Fund announced that the former Inspector General Huang Jinsong has retired and resigned, and Wang Zhongkun has been appointed as the new Inspector General. According to his resume, Wang Zhongkun has served as a member of the Regulatory Department and Secretary of the Secretariat of China Construction Bank Co., Ltd., Secretary of the President’s Office of China Cinda Asset Management Co., Ltd., Secretary of the Board of Directors of Hongyuan Securities Co., Ltd., Marketing Director, Deputy General Manager, and General Manager of the Marketing Department of Cinda Australia Bank Fund Management Co., Ltd., Vice Chairman and Chairman of the Strategic Planning Committee of Leading Biological Agriculture Co., Ltd., Investment Manager of Fengtu Beikong (Ningbo) Investment Management Co., Ltd., and Deputy General Manager of Tianyi Xingchen (Beijing) Technology Co., Ltd. No.2: Yuan Qingwei, the newly appointed General Manager of ...
- Source: drugdu
- 85
- June 11, 2025
Lindsay Huse on Health in Douglas County, Nebraska

The tumult of President Donald Trump’s second term has trickled down from federal agency headquarters in Washington, D.C., to state and local health departments, kicking off a new era fraught with uncertainty even as some of these leaders on the front lines of public health are still struggling to recover from the upheaval caused by the COVID-19 pandemic. What began as a gutting of the federal health workforce has expanded into what some fear could be the upending of the nation’s public health infrastructure. Thus far, the Trump administration has moved to cut approximately $12 billion in funding that had been allocated to state and local health departments, though a federal judge has temporarily blocked cuts for multiple states. As part of our series, Public Health Under Pressure, U.S. News is speaking with stakeholders and officials at local and state health departments around the country to get a better understanding ...
- Source: drugdu
- 69
- June 11, 2025
Salmonella Outbreak Triggers Egg Recall in 9 States

MONDAY, June 9, 2025 (HealthDay News) — A salmonella outbreak tied to a major egg recall has sickened nearly 80 people and sent at least 21 to the hospital, health officials have said. The outbreak has been linked to brown organic and brown cage-free eggs distributed by the August Egg Company, according to a June 6 notice from the U.S. Food and Drug Administration (FDA). More than 1.7 million eggs are being recalled. The Hilmar, Calif.—based company distributed the eggs between February and May. They were sold in nine states: Arizona, California, Illinois, Indiana, Nebraska, New Mexico, Nevada, Washington and Wyoming, the Associated Press reported. The U.S. Centers for Disease Control and Prevention (CDC) said 79 people across seven states have gotten sick from the same strain of salmonella linked to the recalled eggs. Salmonella can cause diarrhea, fever, vomiting, stomach cramps and dehydration. Most people recover within a week, ...
- Source: drugdu
- 53
- June 11, 2025
Yipinhong subsidiary’s Dexmedetomidine Hydrochloride Injection obtains registration certificate

June 9, Poinsettia(300723) issued an announcement that the company’s wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical Co., Ltd. recently obtained the “Drug Registration Certificate” for Dexmedetomidine Hydrochloride Injection approved and issued by the State Food and Drug Administration. This drug is a Class 3 chemical drug and is mainly used for sedation during endotracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia, as well as sedation in intensive care patients. Continuous infusion should not exceed 24 hours. In the first quarter of 2025, Yipinhong achieved revenue of 377 million yuan and net profit attributable to shareholders of the parent company of 56.59 million yuan. https://finance.eastmoney.com/a/202506093425539592.html
- Source: drugdu
- 63
- June 11, 2025
Jianyou Holdings’ subsidiary obtains FDA approval for relocation of daunorubicin hydrochloride injection production site

On June 9, Jianyou shares(603707) announced that its subsidiary Meitheal Pharmaceuticals, Inc. recently obtained the approval letter for the transfer of the production site of daunorubicin hydrochloride injection (20mg/4mL, ANDA No.: 065035) issued by the U.S. FDA, approving the production at Jianjin Pharmaceutical Co., Ltd. The drug is suitable for the treatment of adult acute non-lymphocytic leukemia and can be used in combination with other anticancer drugs. The announcement mentioned that the company has invested about 830,000 yuan in research and development costs in the project of relocating the production site of daunorubicin hydrochloride injection. The newly approved product will be marketed in the United States and is expected to have a positive impact on the company’s operating performance. In the first quarter of 2025, Jianyou Shares achieved revenue of 885 million yuan and net profit attributable to shareholders of the parent company of 84.71 million yuan. https://finance.eastmoney.com/a/202506093425522822.html
- Source: drugdu
- 55
- June 11, 2025
Erkang Pharmaceutical’s Vitamin B6 Injection Passed Consistency Evaluation

On June 9, Erkang Pharmaceutical(300267) released an announcement, vitaminThe B6 injection 1ml:100mg specification has passed the generic drug quality and efficacy consistency evaluation. The company recently received the “Notice of Approval of Supplementary Drug Application” approved by the State Drug Administration, with the approval number of National Medicine Standard H20258096. The drug is mainly used for the prevention and treatment of vitamin B6 deficiency and is included in the “National Basic Medical Insurance”, Work-related Injury Insurance and Maternity Insurance Drug List (2024)”, which is a Class A medical insurance drug. In the first quarter of 2025, Erkang Pharmaceutical achieved revenue of 354 million yuan and net profit attributable to shareholders of the parent company of 28.11 million yuan. https://finance.eastmoney.com/a/202506093425512121.html
- Source: drugdu
- 59
- June 11, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.